Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Angiotensin II Receptor Blockers in Diabetic Patients with Advanced Chronic Kidney Disease
TCTR20210526006Not yet recruiting
- Sponsor
- Thammasat University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of resomelagon in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), sponsored by Thammasat University. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
resomelagon
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on TCTR20210526006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210526006.